|
CDC14B expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | <1E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.62447832963153E-12 |
| Normal-vs-Stage2 |
1.66822111680176E-12 |
| Normal-vs-Stage3 |
<1E-12 |
| Normal-vs-Stage4 |
1.62447832963153E-12 |
| Stage1-vs-Stage2 |
3.810100E-02 |
| Stage1-vs-Stage3 |
8.877900E-02 |
| Stage1-vs-Stage4 |
1.92519999997476E-06 |
| Stage2-vs-Stage3 |
3.804600E-03 |
| Stage2-vs-Stage4 |
1.33950000003047E-06 |
| Stage3-vs-Stage4 |
7.715300E-03 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.62458935193399E-12 |
| Normal-vs-AfricanAmerican |
6.43007869172152E-12 |
| Normal-vs-Asian |
<1E-12 |
| Caucasian-vs-AfricanAmerican |
9.438400E-01 |
| Caucasian-vs-Asian |
9.403600E-01 |
| AfricanAmerican-vs-Asian |
9.083600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.62447832963153E-12 |
| Normal-vs-Female |
<1E-12 |
| Male-vs-Female |
6.281600E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.62447832963153E-12 |
| Normal-vs-Age(41-60Yrs) |
<1E-12 |
| Normal-vs-Age(61-80Yrs) |
1.62447832963153E-12 |
| Normal-vs-Age(81-100Yrs) |
5.74989999999609E-05 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
9.004800E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
6.637400E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
7.072200E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
7.434800E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
6.900400E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
6.412600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
3.93290000000324E-05 |
| Classical-VS-Follicular |
1.75336999999054E-05 |
| Classical-VS-Other |
9.647800E-01 |
| Classical-VS-Normal |
1.62447832963153E-12 |
| Tall-VS-Follicular |
6.58150201005014E-11 |
| Tall-VS-Other |
3.962500E-02 |
| Tall-VS-Normal |
1.62436730732907E-12 |
| Follicular-VS-Other |
1.684450E-01 |
| Follicular-VS-Normal |
2.36366481942696E-13 |
| Other-VS-Normal |
2.2044000003163E-07 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.62436730732907E-12 |
| Normal-vs-N1 |
<1E-12 |
| N0-vs-N1 |
1.980610E-04 |
|
|
